Pharmacogenomics Results Affect Patients' Plan of Care and Changes in Medication Prescription(s)

Data Collection Analysis Business Management200 enrolled

Overview

Current providers' standard operating procedures on pharmacogenomic testing patients

The general design of this study is collecting data and reviewing Principal Investigators' Standard Operating Procedures on Pharmacogenomic testing and changes made to their specific SOP.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Pharmacogenomic

Interventions

pharmacogenomicGENETIC

Standard Operating Procedures on Pharmacogenomic testing and changes made to specific SOP

Eligibility

Sex: ALLMin age: 18 YearsMax age: 64 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Must be a Medical Practitioner * Medical Doctor (MD) * Doctor of Osteopathic (DO) * Physician Assistant (PA) * Advanced Practice Registered Nurse (APRN) * Nurse Practioner (NP) * Must have a current standard operating procedure that includes obtaining/reviewing medical history. Exclusion Criteria: * Government-funded insurance data cannot be included in the study.

Locations (1)

DCABM

Land O' Lakes, Florida, United States

Outcomes

Primary Outcomes

Provider Structures and Processes

Plan of Care Changes due to Pharmacogenomic testing. Provider based observational survey system on the health and well-being of patients and populations

Time frame: 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.